EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer

Stefano Crippa, Giuseppe Malleo, Vincenzo Mazzaferro, Serena Langella, Claudio Ricci, Fabio Casciani, Giulio Belfiori, Sara Galati, Vincenzo D'Ambra, Gabriella Lionetto, Alessandro Ferrero, Riccardo Casadei und 4 weitere

JAMA Surgery · 01.10.2024 · 159 (10) · 1139

DOI: 10.1001/jamasurg.2024.2485 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Surgery, erschienen am 01.10.2024. Verfasst von Stefano Crippa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pancreatic Surgery, Pancreas Translational and Clinical Research Center, San Raffaele Scientific Institute, Vita-Salute San Raffaele Univ…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Pancreatectomy, Medical Futility. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance There are currently no clinically relevant criteria to predict a futile up-front pancreatectomy in patients with anatomically resectable pancreatic ductal adenocarcinoma.

Objectives

To develop a futility risk model using a multi-institutional database and provide unified criteria associated with a futility likelihood below a safety threshold of 20%. Design, Setting, and Participants This retrospective study took place from January 2010 through December 2021 at 5 high- or very high-volume centers in Italy. Data were analyzed during April 2024. Participants included consecutive patients undergoing up-front pancreatectomy at the participating institutions. Exposure Standard management, per existing guidelines. Main Outcomes and Measures The main outcome measure was the rate of futile pancreatectomy, defined as an operation resulting in patient death or disease recurrence within 6 months. Dichotomous criteria were constructed to maintain the futility likelihood below 20%, corresponding to the chance of not receiving postneoadjuvant resection from existing pooled data.

Results

This study included 1426 patients. The median age was 69 (interquartile range, 62-75) years, 759 patients were male (53.2%), and 1076 had head cancer (75.4%). The rate of adjuvant treatment receipt was 73.7%. For the model construction, the study sample was split into a derivation (n = 885) and a validation cohort (n = 541). The rate of futile pancreatectomy was 18.9% (19.2% in the development and 18.6% in the validation cohort). Preoperative variables associated with futile resection were American Society of Anesthesiologists class (95% CI for coefficients, 0.68-0.87), cancer antigen (CA) 19.9 serum levels (95% CI, for coefficients 0.05-0.75), and tumor size (95% CI for coefficients, 0.28-0.46). Three risk groups associated with an escalating likelihood of futile resection, worse pathological features, and worse outcomes were identified. Four discrete conditions (defined as CA 19.9 levels-adjusted-to-size criteria: tumor size less than 2 cm with CA 19.9 levels less than 1000 U/mL; tumor size less than 3 cm with CA 19.9 levels less than 500 U/mL; tumor size less than 4 cm with CA 19.9 levels less than 150 U/mL; and tumor size less than 5 cm with CA 19.9 levels less than 50 U/mL) were associated with a futility likelihood below 20%. Both disease-free survival and overall survival were significantly longer in patients fulfilling the criteria. Conclusions and relevance In this study, a preoperative model (MetroPancreas) and dichotomous criteria to determine the risk of futile pancreatectomy were developed. This might help in selecting patients for up-front resection or neoadjuvant therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsPancreatectomyMedical FutilityHumansMaleFemaleAgedRetrospective StudiesMiddle AgedCarcinoma, Pancreatic DuctalItalyRisk Assessment

Autor:innen und Institutionen

  • Division of Pancreatic Surgery, Pancreas Translational and Clinical Research Center, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Unit of Pancreatic Surgery, Pancreas Institute, University of Verona Hospital Trust, GB Rossi Hospital, Verona, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milano, Italy and HPB Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Department of General and Oncological Surgery, Mauriziano Hospital, Turin, Italy.
  • Division of Pancreatic Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy.

Zitieren

APA

Crippa, S., Malleo, G., Mazzaferro, V., Langella, S., Ricci, C., Casciani, F., Belfiori, G., Galati, S., D'Ambra, V., Lionetto, G., Ferrero, A., Casadei, R., Ercolani, G., Salvia, R., Falconi, M., & Cucchetti, A. (2024). Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. JAMA Surgery, 159(10), 1139. https://doi.org/10.1001/jamasurg.2024.2485

Vancouver

Crippa S, Malleo G, Mazzaferro V, Langella S, Ricci C, Casciani F, et al. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. JAMA Surgery. 2024;159(10):1139. doi:10.1001/jamasurg.2024.2485

BibTeX
@article{Crippa2024,
  author = {Crippa, Stefano and Malleo, Giuseppe and Mazzaferro, Vincenzo and Langella, Serena and Ricci, Claudio and Casciani, Fabio and Belfiori, Giulio and Galati, Sara and D'Ambra, Vincenzo and Lionetto, Gabriella and Ferrero, Alessandro and Casadei, Riccardo and Ercolani, Giorgio and Salvia, Roberto and Falconi, Massimo and Cucchetti, Alessandro},
  title = {Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer},
  journal = {JAMA Surgery},
  year = {2024},
  volume = {159},
  number = {10},
  pages = {1139},
  doi = {10.1001/jamasurg.2024.2485}
}
Kostenlos starten →